



NOVA

University of Newcastle Research Online

nova.newcastle.edu.au

Anthony Kicic.; Emma de Jong.; Kak-Ming Ling.; Kristy Nichol.; Denise Anderson.; Peter A.B. Wark.; Darryl A. Knight.; Anthony Bosco.; Stephen M. Stick. "Assessing the unified airway hypothesis in children via transcriptional profiling of the airway epithelium. Published in *Journal of Allergy and Clinical Immunology* Vol. 145, Issue 6, p. 1562-1573 (2020)

**Available from:** <http://dx.doi.org/10.1016/j.jaci.2020.02.018>

© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license  
<http://creativecommons.org/licenses/by-nc-nd/4.0/>

**Accessed from:** <http://hdl.handle.net/1959.13/1420698>



26 9. Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia

27 10. Hunter Medical Research Institute, Priority Research Centre for Asthma and Respiratory  
28 Disease, New Lambton Heights, NSW, Australia

29

30 \* authors contributed equally.

31

32 Corresponding author: Associate Professor Anthony Kicic, Telethon Kids Institute, Nedlands,  
33 Perth, 6009, Western Australia, Australia Ph: (618) 6319 1799. email:  
34 [Anthony.Kicic@telethonkids.org.au](mailto:Anthony.Kicic@telethonkids.org.au)

35

36 This article has an online data supplement, which is accessible from this issue's table of  
37 content at [www.atsjournals.org](http://www.atsjournals.org)

38

39 **FUNDING:** This work was supported by a grant from Asthma Australia. SMS is a NHMRC  
40 Practitioner Fellow. AK is a Rothwell Family Fellow. AB is supported by a Fellowship from  
41 the Simon Lee Foundation.

42

43 **AUTHOR DECLARATION:** All authors declare that there are no conflicts of interest  
44 financial or otherwise with this manuscript submission.

45

46 **AUTHOR CONTRIBUTION:** Study conception and design: SMS, AK, PAW, DAK, AB;  
47 Sample recruitment and clinical expertise: AK, KML, KN, SMS, PAW; Experimental work:  
48 AK, KML, KN, EJ, DA, AB; Analysis and interpretation of data: AK, EJ, SMS, PAW, DAK,

49 AB, DA; Drafting of manuscript: AK, EJ, SMS, DAK, AB, PAW; Critical revision of  
50 manuscript: SMS, AK, EJ, KML, KN, DA, PAW, DAK, AB

51

52 **TOTAL WORD COUNT: 5051**

53

Journal Pre-proof

54 **ABSTRACT (254)**

55 **Background:** Emerging evidence suggests that disease vulnerability is expressed throughout  
56 the airways; the so-called “unified airway hypothesis” but the evidence to support this is  
57 predominantly indirect. **Objectives:** To establish the transcriptomic profiles of the upper and  
58 lower airway and determine their level of similarity irrespective of airway symptoms  
59 (wheeze) and allergy. **Methods:** We performed RNA-sequencing on upper and lower airway  
60 epithelial cells from 63 children with or without wheeze and accompanying atopy, utilizing  
61 differential gene expression and gene co-expression analyses to determine transcriptional  
62 similarity. **Results:** We observed ~91% homology in the expressed genes between the two  
63 sites. When co-expressed genes were grouped into modules relating to biological functions,  
64 all were found to be conserved between the two regions, resulting in a consensus network  
65 containing 16 modules associated with ribosomal function, metabolism, gene expression,  
66 mitochondrial activity and anti-viral responses through interferon activity. Although symptom  
67 associated gene expression changes were more prominent in the lower airway, they were  
68 reflected in nasal epithelium and included; *IL1RL1*, *PTGS1*, *CCL26* and *POSTN*. Through  
69 network analysis we identified a cluster of co-expressed genes associated with atopic-wheeze  
70 in the lower airway, which could equally distinguish atopic and non-atopic phenotypes in  
71 upper airway samples. **Conclusions:** We show that the upper and lower airway are  
72 significantly conserved in their transcriptional composition, and that variations associated  
73 with disease are present in both nasal and tracheal epithelium. Findings from this study  
74 supporting a unified airway imply that clinical insight regarding the lower airway in health  
75 and disease can be gained from studying the nasal epithelium.

76

77

78 **KEY MESSAGES:**

79 • Nasal and tracheal epithelium exhibit similar transcriptional profiles, with some minor  
80 differences reflective of site-specific function

81 • Gene expression changes associated with wheeze and atopy are reflected in both  
82 tracheal and nasal epithelium

83 • These changes include some genes that are well characterised in the context of asthma  
84 (*CLCA1*, *IL1RL1*, *CCL26* and *POSTN*)

85

86 **CAPSULE SUMMARY:**

87 We identified 91% transcriptional similarity between the upper and lower airway supporting  
88 the ‘unified airway hypothesis’. Furthermore, gene expression changes associated with  
89 wheeze and atopy were also conserved in both regions.

90

91 **KEYWORDS:** airway epithelium, unified airway hypothesis, transcriptomics, gene  
92 expression, biological processes

93

94 **ABBREVIATIONS:** American Thoracic Society (ATS), Cadherin 10 (CDH10), Cadherin  
95 15 (CDH15), Cadherin 19 (CDH19), Chemokine (C-C motif) Ligand 5 (CCL5), Chemokine  
96 (C-C motif) Ligand 26 (CCL26), Chloride Channel Accessory 1 (CLCA1), Chronic  
97 Obstructive Pulmonary Disease (COPD), Cystatin 1 (CST1), Cystatin 2 (CST2), Cystatin 4  
98 (CST4), Cystic Fibrosis (CF), Granulocyte-Macrophage Colony Stimulating Factor (GM-  
99 CSF), Interleukin (IL), Interleukin 1 Receptor Like 1 (IL1RL1), International Study of Asthma  
100 and Allergies in Children (ISAAC), Keratin 1 (KRT1), Keratin 23 (KRT23), Keratin 33A  
101 (KRT33A), Keratin 34 (KRT34), Keratin 36 (KRT36), Keratin 37 (KRT37), Keratin 71

102 (KRT71), Nasal Epithelial Cells, (NEC)Neurotrophic Receptor Tyrosine Kinase 1 (NTRK1),  
103 Periostin (POSTN), Prostaglandin-Endoperoxide Synthase 1 (PTGS1), Protocadherin 8  
104 (PCDH8).Protocadherin 11 X-linked (PCDH11X), Radioallergosorbent Test (RAST),  
105 Tracheal Epithelial Cells (TEC), Weighted Gene Co-expression Network Analysis  
106 (WGCNA),

107 **INTRODUCTION**

108 The ‘unified airway hypothesis’ postulates that diseases of the upper and lower airway are  
109 both manifestations of a single process<sup>1</sup>. Its principle lies in the concept of a continuous  
110 respiratory tract lined with respiratory epithelial cells encompassing the nose and middle ear,  
111 which extends to the terminal bronchioles<sup>2</sup>. Thus, under disease settings, a pathological  
112 process in one region of the airway would affect the function of the entire airway<sup>3</sup>. This is  
113 particularly evident in chronic airway diseases such as chronic rhinosinusitis and asthma.  
114 These diseases have traditionally been evaluated and treated as separate disorders but  
115 advances in the understanding and knowledge of the underlying processes have moved  
116 opinion towards the concept of unifying their management<sup>4</sup>.

117

118 The upper and lower respiratory tracts share many anatomical and histological properties, as  
119 well as the airflow into and out of the lungs<sup>5</sup>. They also share a common susceptibility and  
120 response to different allergens, infections and pollutants<sup>6-9</sup>. In the setting of asthma,  
121 comparable inflammatory cell profiles, particularly in T-cells, mast cells and macrophages  
122 have been reported for both the upper and lower respiratory tracts<sup>10, 11</sup>. In addition, similar  
123 chemokine and cytokine production have also been reported including interleukin (IL) 5, IL-  
124 4, IL-13, Chemokine (C-C motif) ligand 5 (CCL5), and granulocyte-macrophage colony  
125 stimulating factor (GM-CSF) levels<sup>12, 13</sup>. In contrast, eosinophil infiltration, epithelial  
126 shedding and basement membrane thickness have all been reported to be greater in lower  
127 airway of asthmatic patients<sup>10, 14</sup>. Furthermore, the highly-developed vasculature evident in  
128 the nose contrasts with the smooth muscle bundles that surround the tracheal/ bronchial  
129 airways<sup>15</sup>. This dichotomy highlights the need for additional clarification as to whether there  
130 exists a unified airway, especially since the complex interactions between the nose and lung

131 are not well understood but may have important implications for the pathogenesis of  
132 respiratory diseases.

133

134 In this study, we implemented a transcriptional profiling-based approach to systematically  
135 analyze 63 children with or without atopy and/or wheeze to explore similarities and  
136 differences in gene expression between the upper and lower respiratory tracts. Specifically,  
137 we tested the hypothesis that the transcriptomic profiles of both the nasal and lower tracheal  
138 epithelium would be comparable. Using weighted correlation network analysis on all study  
139 participants, we identified 16 modules of co-expressed (and functionally enriched) genes to be  
140 conserved between the lower and upper airway. Further, we identified an atopic-wheeze gene  
141 signature within tracheal epithelium that was equally able to distinguish between atopic and  
142 non-atopic phenotypes within nasal epithelium. These findings provide insight into the  
143 intrinsic biological differences inherent to epithelium in the context of airway symptoms and  
144 support the concept of a unified airway. Our data suggests that overall, there is conservation  
145 of the underlying transcriptional networks between the lower and upper airway epithelium in  
146 terms of the biological processes that are active at each site, however some regional  
147 specificity in terms of relative gene expression levels is evident.

148

149

150 **METHODS**151 *Study population*

152 The study was approved by the Perth Children's Hospital and St John of God Hospital's  
153 Human Ethics Committees and written consent was obtained from each participant's legal  
154 guardian after being fully informed about the purpose of the study. Airway samples were  
155 obtained from 63 children undergoing elective surgery for non-respiratory related conditions  
156 (Table 1) and those symptomatic for an existing bacterial or viral chest infection were  
157 excluded from the study. Children were identified as having a history of wheeze based on  
158 reported chest wheezing on auscultation by each participant's treating physician. All had  
159 regular documented episodes of recurrent and persistent wheeze in the preceding year,  
160 complemented with a history of documented episodes greater than 12 months prior to  
161 recruitment. A smaller number of older children with recurrent wheeze were also diagnosed  
162 with asthma which was defined as physician-diagnosed based upon physician documented  
163 wheezing episodes in the 12-months preceding their recruitment and confirmed by positive  
164 responses on the International Study of Asthma and Allergies in Children (ISAAC) and  
165 American Thoracic Society (ATS) respiratory questionnaires<sup>16,17</sup>. Atopy was determined by a  
166 positive radioallergosorbent test (RAST) to a designated panel of allergens (house dust mite,  
167 mixed grasses, various animal hair, and different moulds). Children were stratified into four  
168 groups for sub-analysis including; (1) healthy, (2) atopy no wheeze (atopy alone), (3) wheeze  
169 no atopy (wheeze alone) and (4) wheeze and atopy.

170

171 *Sampling procedure and cell types*

172 Lower Airway Epithelial Cells (AECs) were harvested via trans-laryngeal, non-bronchoscopic  
173 brushing of the tracheal mucosa of children via an endotracheal tube as previously

174 described<sup>18-20</sup>. Matched upper AECs were also obtained and was executed using a rotational  
175 movement of the brush against the nasal turbinate. The brush tip was then inserted and cut off  
176 into cold sterile media (RPMI- 1640) containing 20% heat inactivated fetal calf serum (FCS).  
177 The process was repeated at least once more before the samples were transported back to the  
178 laboratory on ice for immediate processing. An unsheathed soft nylon cytology brush (BC  
179 25105; Olympus) was used to sample both regions and performed by the same physician for  
180 all participants to minimize sample variance and potential study confounders.

181

### 182 ***RNA isolation and sequencing***

183 Collection tubes, containing nasal or tracheal AECs were vortexed for a period to disrupt the  
184 cells off the brush and the larger cell clumps. The brushes are removed and placed into  
185 another collection tube which is then vortexed for a period to release any remaining cells. The  
186 collection media was then pooled, centrifuged at 500 x g for 7 minutes at 4°C, and  
187 resuspended in 5 mL of collection media. A cell count was then performed and approximately  
188 one million AECs were fractionated out, pelleted and resuspended in 350 µL RLT buffer  
189 containing 1% (v/v) β-mercaptoethanol (QIAGEN) and stored at -80°C until all samples were  
190 obtained. RNA was extracted using the Ambion Purelink® RNA mini kit (Thermo Scientific)  
191 per the manufacturer's instructions and appropriate RNA samples shipped to the Australian  
192 Genome Research Facility for library preparation (TruSeq Stranded mRNA Library Prep Kit,  
193 Illumina) and sequencing (Illumina HiSeq2500, 50-bp single-end reads, v4 chemistry). RNA  
194 integrity was determined using an Agilent 2100 Bioanalyzer (Agilent Technologies); median  
195 RNA integrity number was 8.3 (range 7.8–9). The RNA-seq data have been deposited in  
196 NCBI's Gene Expression Omnibus<sup>21</sup>, and are accessible through GEO Series accession  
197 number GSE118761 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118761>).

198 ***Data analysis***

199 Raw RNA-sequencing data was quality assessed using FastQC<sup>22</sup> (v0.11.3) and aligned to the  
200 human genome (hg19) using HISAT2<sup>23</sup> (v2.0.4). Four samples from different individuals (two  
201 nasal, two tracheal) failed quality control checks, and were excluded from downstream  
202 analyses. Gene-level quantitation of aligned reads was performed using the  
203 `summarizeOverlaps()` function from the BioConductor *GenomicAlignments* package<sup>24</sup>,  
204 and post-alignment quality control using SAMStat<sup>25</sup> (v1.5.2). Differentially expressed genes  
205 were identified between tracheal and nasal epithelial samples using the Bioconductor package  
206 *limma-voom*<sup>26</sup>, with paired samples taken into account through the  
207 `duplicateCorrelation()` function. Differentially expressed genes were identified  
208 between study groups using the Bioconductor package DESeq2<sup>27</sup>, with model adjustments for  
209 age and sex. P-values for both analyses were adjusted for multiple testing using the  
210 Benjamini-Hochberg method, and those  $<0.05$  were considered significant. The weighted  
211 gene co-expression network analysis (WGCNA)<sup>28</sup> algorithm was used to construct signed  
212 networks for nasal and tracheal epithelial cells separately, based on gene expression from all  
213 study participants. Biological characterisation of the differentially expressed genes or  
214 consensus network modules was performed using InnateDB<sup>29</sup> to identify significantly over-  
215 represented pathways. For comparison to the skin dataset, raw fastq sequencing files were  
216 downloaded from the Gene Expression Omnibus<sup>21</sup> (GSE54456) and processed through the  
217 same pipeline as our airway epithelial samples, for optimal comparison between tissues. The  
218 skin dataset was filtered and normalised using identical methods as for the airway epithelial  
219 samples, as described in text.

220

221 ***Statistical methods***

222 Statistical analyses of demographic data were performed using Prism (v7; GraphPad  
223 Software). We used the Kruskal-Wallis test with Dunn's multiple comparisons test for  
224 continuous variables (data for each group were checked using the D'Agostino & Pearson  
225 normality test) and Chi-square tests for categorical variables. All other statistics obtained  
226 outside of InnateDB or Ingenuity Pathway Analysis were performed in the R environment  
227 (v3.3.3). Correlation of average gene expression between tracheal and nasal epithelium was  
228 using the Kendall rank correlation coefficient for non-parametric data. The  
229 `modulePreservation()` function (which calculates pair-wise module preservation  
230 statistics) was used to compare individual co-expression networks for tracheal and nasal  
231 epithelium, where results are summarised into a Z-score of overall module preservation  
232 between the networks.

233

234 **RESULTS**235 *Comparison of gene expression profiles between tracheal and nasal epithelium,*  
236 *independent of wheeze or atopy.*

237 Demographic data for all study participants is presented in Table 1, and a summary of all  
238 analyses performed is presented in Figure E1. RNA-sequencing resulted in an average of 20  
239 million mapped reads per sample (range 13.7–25 million). To initially assess the composition  
240 of tracheal and nasal epithelium across all samples, we compared the overlap of expressed  
241 genes between the two sites, using a count per million (CPM) threshold corresponding to a  
242 count of at least ten in all nasal or tracheal samples. This is a standard filtering strategy for  
243 removing low or non-expressed genes<sup>30</sup>. We identified 16,645 and 16,720 genes expressed in  
244 tracheal and nasal epithelium respectively (independent of wheeze or atopy) of which 15,864  
245 (~91%) were expressed in both sites, while the remainder were more frequently expressed in  
246 either site (Figure 1A). Overall, gene expression was highly correlated between tracheal and  
247 nasal epithelium (Kendall's tau = 0.82, p-value < 2.2E-16) (Figure 1B). Next, to confirm if  
248 our gene expression profiles were specific to the airway, or common to other types of  
249 epithelium, we compared our dataset to that derived from healthy skin punch biopsies<sup>31</sup>  
250 (n=82). Using the same filtering strategy as for the airway samples, we identified 15,784  
251 genes expressed in the skin epithelium, of which 74–75% were also expressed in the airway  
252 epithelium (Figure E2). In general, weaker correlations were observed between gene  
253 expression profiles from the skin and each airway tissue (Kendall's tau = 0.46 and 0.50 for  
254 correlations with tracheal and nasal samples, respectively; Figure E2). In addition, to more  
255 thoroughly investigate the differences between airway sites, we tested for differentially  
256 expressed genes between tracheal and nasal epithelial samples independent of wheeze/atopy,  
257 and identified 2,467 genes with an absolute fold-change difference in expression >2 between  
258 tissues (Table E1). We then ranked these genes by highest absolute fold-change, to

259 characterise the most divergent genes. Genes with the greatest dichotomy in expression that  
260 were most highly expressed in tracheal epithelium included *MARCO* (involved in innate  
261 immune responses), *FABP4* (functions in lung inflammation/angiogenesis), the surfactant  
262 protein-coding gene *SFTA3* and *NKX2-1* (transcription factor involved in lung development).  
263 Those most highly expressed in nasal epithelium included a range of transcription factors  
264 (*FOXP1*, *PAX7*, *OTX2*, *SIX3*, *SP8*, *PAX3*) alongside the keratin encoding gene *KRT24*.

265  
266 We next constructed weighted co-expression gene networks for tracheal and nasal epithelium  
267 in parallel (across all samples), as a holistic approach to understanding the functional  
268 organisation of the transcriptome at each site<sup>32</sup>. This analysis works to identify clusters (or  
269 modules) of genes with similar patterns of gene expression across each tissue, and provides  
270 biological insight based on the principal that genes with highly correlated patterns of  
271 expression are likely to participate in the same biological process. Here, we identified 17  
272 network modules within tracheal epithelium, and 8 modules within the nasal epithelium. We  
273 next identified significantly over-represented biological pathways and gene ontology terms  
274 for each module in the tracheal and nasal network (Tables E2 and E3 in this article's Online  
275 Repository at [www.jacionline.org](http://www.jacionline.org)). A comparison of these two site-specific networks  
276 revealed a significant overlap in structure, i.e. each nasal network module corresponded to  
277 one or more tracheal network modules (Figure 2A). This was confirmed through additional  
278 module preservation statistics which test how well the modules from one network, are  
279 preserved in another. Each network module from the nasal network was significantly  
280 preserved in the tracheal network (Table 2) and vice versa (Table 3); a Z-score >10 indicates  
281 strong evidence of module preservation, and the average across networks was 36.8 (range 14–  
282 67). Given the similarities between the tracheal and nasal networks, we next built a consensus  
283 network, where the resulting network modules represent robust gene co-expression patterns

284 common to both tracheal and nasal epithelium. The consensus network contained 16 modules  
285 of co-expressed genes (Figure 2B), and each module of the consensus network significantly  
286 overlapped with at least one module from both tracheal and nasal epithelial networks (Figure  
287 E3 in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)). Most of the consensus network  
288 modules were associated with generalised cellular processes (ribosomal function, metabolism,  
289 gene expression, mitochondrial activity), while two modules were associated with immune  
290 responses, one being specific for interferon mediated anti-viral responses (Table E4 in this  
291 article's Online Repository at [www.jacionline.org](http://www.jacionline.org)). To assess the relative expression of each  
292 consensus network module in each tissue and within each study group, the median fold-  
293 change difference in expression of the consensus module genes was measured between  
294 tracheal and nasal samples, and was less than one across all phenotypes (Figure 2C). This  
295 suggests a modest difference in the relative expression of consensus modules between tissues,  
296 independent of atopy/wheeze (Figure E4 this article's Online Repository at  
297 [www.jacionline.org](http://www.jacionline.org) presents the results for each study group individually). Of note, modules  
298 associated with cilium assembly and cell cycle activity (yellow and blue) were more highly  
299 expressed in the tracheal epithelium, while nasal epithelium was associated with increased  
300 expression of modules involving growth and metabolism (red and brown). Taken together,  
301 these results demonstrate overall conservation of the underlying transcriptional networks  
302 between tracheal and nasal epithelium, while specific gene expression differences relate to  
303 site-specific functions.

304

305 ***Gene expression changes associated with wheeze and atopy occur in both nasal and***  
306 ***tracheal epithelium***

307 To identify gene expression changes associated with atopy and or wheeze within the  
308 epithelium, differential gene expression analyses were performed contrasting each group

309 against healthy controls. Specifically, these comparisons inform on the gene expression  
310 changes related to the combined effect of wheeze and atopy (wheeze with atopy vs healthy  
311 controls), atopy only (atopy vs healthy controls) or wheeze only (wheeze vs healthy controls).  
312 As an alternative approach to identifying gene signatures attributed to wheeze only, we also  
313 compared atopics with or without wheeze. The results from each of the four comparisons  
314 across both tracheal and nasal epithelium are summarised in Table 4 (Tables E5–E12 in this  
315 article’s Online Repository at [www.jacionline.org](http://www.jacionline.org)). Comparisons related to the combined  
316 effect of atopy and wheeze yielded the largest gene expression differences in both tissues,  
317 while overall, disease associated changes were more prominent in the tracheal epithelium  
318 (greater numbers of differentially expressed genes compared to nasal epithelium).  
319 Importantly, we observed a partial overlap between the lists of genes generated from each  
320 contrast across tissues, which overall showed strong agreement in terms of fold-change values  
321 (Tables E13–E16 and Figure E5 in this article’s Online Repository at [www.jacionline.org](http://www.jacionline.org)).  
322 The greatest overlap was evident for contrasts between wheeze with atopy and healthy  
323 controls; 49 genes were differentially expressed in both the lower and upper airway  
324 epithelium, including several well characterised asthma-associated genes (*IL1RL1*, *PTGS1*,  
325 *CCL26* and *POSTN*).

326

327 ***Lower airway gene-signatures in atopic wheezers can distinguish between groups in upper***  
328 ***airway samples***

329 We next sought to obtain a more detailed understanding of the molecular mechanisms that  
330 characterise the wheeze-associated signatures in the upper and lower airways through  
331 WGCNA, which provides a holistic view of the functional organisation of the gene expression  
332 program. Separate networks were constructed for the tracheal and nasal epithelial samples  
333 based on genes with significant variation in expression across samples (to capture genes with

334 intrinsic biological variation between phenotypes). The inclusion of a variance-based filter  
335 contrasts with the previous network analysis, which was performed on a transcriptome-wide  
336 scale. This analysis defined nine modules (or clusters) of co-expressed genes within the  
337 tracheal epithelium (Figure 3A), and six modules within the nasal epithelium (Figure E6A in  
338 this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)). To determine which network  
339 module(s) were perturbed in relation to wheeze or atopy, each module was checked for  
340 enrichment of differentially expressed genes across all four contrasts. Module E within the  
341 tracheal epithelial network was highly enriched for genes associated with wheeze with atopy,  
342 while no other network module (in either tissue) was associated with a disease phenotype  
343 (Figure 3B and Figure E6B-E in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org)).  
344 Herein, module E is referred to as the tracheal wheeze with atopy module. To test whether  
345 differences in these genes were specific to the lower airway, or were also present in the upper  
346 airway, we performed semi-supervised clustering analysis using the 92 genes. Heatmap  
347 visualisation of the 92 genes within this module indicated that overall i) the genes were more  
348 highly expressed in individuals with wheezing with atopy or atopy alone and ii) this  
349 expression pattern and sample clustering was consistent within nasal epithelium (Figure 3C).  
350 Importantly, Principal Component Analysis based on the 92-genes within the tracheal wheeze  
351 with atopy module, could equally distinguish between groups in nasal epithelium (Figure 3D).  
352 Of note, in both upper and lower airway samples, subjects with wheeze and atopy or atopy  
353 alone tended to cluster together, while subjects with wheeze alone clustered more closely with  
354 the healthy controls. This is consistent with the fact that none of the genes within the tracheal  
355 wheeze with atopy module were significantly differentially expressed in relation to wheeze  
356 alone in either tracheal or nasal epithelium (Table E17 in this article's Online Repository at  
357 [www.jacionline.org](http://www.jacionline.org)).

358

359 ***Children with atopy exhibit similar gene expression profiles across nasal and tracheal***  
360 ***epithelium***

361 To capture the most robust changes associated with wheezers with atopy, the twenty most  
362 significantly differentially expressed genes between children with wheeze and atopy and  
363 healthy controls, and the twenty genes with the greatest absolute fold-change difference in  
364 expression were identified in tracheal and nasal epithelium i.e. genes were ranked once by  
365 adjusted p-value, then again by absolute fold-change for each tissue, resulting in four lists.  
366 Five genes (*CST1*, *CST2*, *CST4*, *CLCA1*, *POSTN*) were consistently ranked in the top twenty  
367 genes across all four lists, all of which were significantly up-regulated in children with atopy  
368 (Figure 4). In addition, a first-order protein-protein interaction network containing the  
369 tracheal wheeze with atopy module genes was created to identify the most highly  
370 interconnected genes (hubs; representing key molecules within a network) (Figure E7 in this  
371 article's Online Repository at [www.jacionline.org](http://www.jacionline.org)). Again, the atopic groups exhibited  
372 increased expression for several hub genes (*IL1R1*, *NTRK1*, *KRT1*) across both nasal and  
373 tracheal airway epithelium (Figure 4).

374

375 **DISCUSSION**

376 The upper and lower respiratory tracts form a continuum allowing the passage of air into and  
377 out of the lungs. Despite epidemiological and pathophysiological evidence to suggest a  
378 unified airway, there are also significant differences between these two regions. Although a  
379 unified airway has been inferred, there is conjecture on whether this is in fact the case due to a  
380 lack of direct evidence. The current study is the largest of its kind conducted to directly test  
381 this hypothesis by undertaking a global transcriptomic analysis on freshly isolated nasal and  
382 tracheal epithelial cells from children, with and without atopy and/or wheeze. Our  
383 observations support the hypothesis of unified airway with 91% homology in the types of  
384 genes being expressed in the upper and lower airway. Furthermore, network analysis  
385 illustrated conservation of co-expressed (and functionally enriched) gene modules between  
386 the upper and lower airway which were associated with generalised cellular processes  
387 including; ribosomal function, metabolism, and mitochondrial activity. Furthermore, we  
388 identified gene expression changes associated with wheeze and/ or atopy (*IL1RL1*, *PTGS1*,  
389 *CCL26*, *POSTN*, *CST1*, *CST2*, *CST4*, *CLCA1*, *NTRK1*) that are inherent to both the upper and  
390 lower airway epithelium. Collectively, the findings support the view of a unified airway at the  
391 transcriptomic level and provide rationale for future exploration into functional relationships  
392 between these two regions.

393

394 The few studies that have used transcriptomics to compare nasal and tracheal epithelial cells  
395 have done so under specific airway disease settings including asthma, cystic fibrosis (CF) and  
396 Chronic Obstructive Pulmonary Disorder (COPD), have utilised relatively small sample sizes  
397 (<15), and compared their data with publicly available transcriptomic data sets<sup>33, 34</sup>. In  
398 contrast, our study performed transcriptomic analysis on a paediatric cohort of 63 children  
399 with and without wheeze and/or atopy, using predominantly matched nasal and tracheal

400 samples. This study was also designed and conducted with high stringency with only those  
401 RNA samples meeting the set quality (ratio >1.80), integrity (RIN>7.8) and quantity (>800ng)  
402 standards subsequently sequenced. Procedures were also harmonized for nasal and airway  
403 sampling as well as the processing and extensive training at the initial phase of the study  
404 ensured that the method and location of sampling as well as the subsequent processing was  
405 standardized. We have also minimized sampling and technique confounders to the study by  
406 employing only 1 physician to obtain all samples using the one nylon cytology brush. As a  
407 result, we feel this study has a unique robustness that has enabled detailed and meaningful  
408 analysis of its findings.

409

410 Not surprisingly, we identified a family of keratin genes (*KRT23*, *KRT33A*, *KRT34*, *KRT36*,  
411 *KRT37*, *KRT71*) that were not differentially expressed between sites. Being archetypal lineage  
412 markers, broad commonality between the nasal and tracheal epithelium of these genes support  
413 the concept of a common cell lineage and unified airway. Furthermore, observed similarities  
414 between the nasal and tracheal epithelium in terms of modules/clusters of co-expressed genes  
415 also highlights the globally conserved biological functions across both types of epithelium  
416 irrespective of disease phenotype, although the higher number of modules initially defined in  
417 tracheal epithelium may reflect a higher level of functional complexity in the lower airway.  
418 For example, several tight junction gene expression levels (*CDH10*, *CDH15*, *CDH19*, *CDH9*,  
419 *PCDH11X*, *PCDH8*) were similarly expressed in both the upper and lower airway and suggest  
420 a commonality in barrier function maintenance.

421

422 Further exploration of the genes more highly expressed in the upper airway found that in  
423 addition to olfactory genes (*ORFE129P*, *ORF7E158P*, *ORF7E91P*, *ORF7E99P*) and genes  
424 related to epithelial lineage (*KRT16*, *KRT16P3*, *KRT18P32*, *KRT8P5*, *KRT2*, *KRT24*,

425 *KRT8P1*, *KRT8P38*, *KRTP5-9*), were genes from the uridine 5'-diphospho-  
426 glucuronosyltransferase (UDP) family (*UGT1A10*, *UGT1A7*, *UGT1A8*, *UGT1A2*, *UGT1A3*,  
427 *B3GALT1*, *B3GNT6*, *GALNT13*, *GALNT16*, *GALNT4*). These genes have been found to be  
428 expressed in the lung epithelium<sup>35, 36</sup> in addition to hepatic tissue and collectively act to  
429 remove toxins, endogenous substances and foreign chemicals, which align to the primary  
430 function of the upper airway<sup>37, 38</sup>. Tracheal epithelial cells on the other hand were found to  
431 more highly express tubulin genes (*TUBAL3*, *TUBB8P7*) whose purpose is to direct airway  
432 ciliary function<sup>39 40</sup>. This is corroborated further by the observation that network modules  
433 related to cilium assembly/activity were more highly expressed in the lower airway. Also  
434 prominent in the lower airway were genes related to calcium-activated chloride channels  
435 (*ANO3*, *ANO4*, *ANO5*, *BEST3*, *CADPS*, *CACNG4*, *CACNA1B*, *CACNA1E*, *CACNA1H*) which  
436 regulate and maintain the air surface liquid (ASL) layer at the luminal surface of epithelia,  
437 which is critical for effective mucociliary clearance<sup>41 42</sup>. We then broadened our comparisons  
438 to include the skin in order to determine whether the predominantly unified signature  
439 extended beyond the airway into other epithelial tissues. We identified a lower level of  
440 similarity (75%) in the genes expressed in the skin and the nasal/tracheal epithelium  
441 compared to the similarity observed between nasal and tracheal epithelium (95%), which was  
442 corroborated by weaker correlations observed in the gene expression profiles between the two  
443 sites. Collectively, these results suggest that while the upper and lower airway exhibit  
444 conservation of gene expression for most genes, differential regulation of gene expression  
445 affecting a small subset of genes is evident between the two sites, reflecting site-specific  
446 functions. Furthermore, and probably not surprisingly, our data show that even though there  
447 is overlap in the gene signature patterns between respiratory and non-respiratory epithelium,  
448 there are unique features in the airway that do not extend to other types of epithelium.

449

450 We believe this is the largest study of its kind to compare transcriptional profiles of airway  
451 epithelium between children that exhibit wheeze and atopy using paired nasal and tracheal  
452 primary airway epithelial samples. Our finding of a conserved signature across both epithelial  
453 tissues in children with wheeze and atopy supports other investigations observing similar  
454 transcriptional profiles between nasal and tracheal tissues in the context of lower airway  
455 pathologies including; childhood asthma<sup>43, 44</sup>, COPD<sup>45</sup> and those induced through cigarette-  
456 smoke<sup>46, 47</sup>.

457

458 Interestingly, several identified genes in our wheeze with atopy group have been also  
459 associated with lower airway pathology, namely asthma. Considering the processes that lead  
460 to asthma development start very early in life and persistent wheezing combined with  
461 allergies is a strong-risk factor for its development, overlaps in the expression of particular  
462 genes may be expected. Of relevance to this study, are the five genes representing the most  
463 robust changes in expression associated with wheeze and atopy across both nasal and tracheal  
464 epithelium (*CST1*, *CST2*, *CST4*, *CLCA1* and *POSTN*). *CST1*, *CST2* and *CST4* encode for the  
465 closely related cystatin-S proteins<sup>48</sup> and have previously been reported as significantly  
466 upregulated in bronchial epithelium of mild to moderate asthmatics<sup>49</sup>, and in nasal epithelium  
467 from individuals with allergic rhinitis (*CST1* only<sup>50</sup>). Cystatins are a large family of peptides  
468 that are potent inhibitors of cysteine proteinases and are often referred to as “salivary  
469 cystatins” due to their recognised role as defence proteins within in saliva<sup>51</sup>, even though  
470 cystatin-S proteins are also expressed in both bronchial and nasal lavage fluids<sup>52</sup>. Another  
471 identified gene, *CLCA1* (chloride channel accessory 1) belongs to a family of calcium-  
472 sensitive chloride conductance proteins and as such, is a critical physiological regulator of  
473 chloride transport and mucin expression; *CLCA1* is highly up-regulated in response to IL-13  
474 and can drive mucus production in human airway epithelial cells<sup>53</sup>. The role of *CLCA1* in

475 hypersecretory respiratory diseases including asthma, COPD and cystic fibrosis is well  
476 documented<sup>54, 55</sup>. Finally, POSTN encodes for periostin; a secreted extracellular matrix  
477 protein that is a well-investigated marker of airway remodelling<sup>56</sup>. POSTN expression is  
478 induced downstream of IL-4/IL-13 signalling in human airway epithelial cells<sup>57</sup> and plays a  
479 role in wound healing and pro-fibrogenic processes<sup>58</sup>. Importantly, over-expression of  
480 POSTN delays wound healing in mice<sup>59</sup> and promotes airway hyperresponsiveness and  
481 inflammation<sup>60</sup>. Collectively, the fact that the conserved epithelial-signature associated with  
482 wheeze and atopy identified in this study contains many genes previously identified as  
483 relevant to asthma pathogenesis, highlights the clinical relevance of our findings.

484

485 Several other genes within our conserved epithelial-signature are hallmarks of Th2-driven  
486 inflammation often observed in asthma or are genes in which genetic variation is significantly  
487 associated with asthma risk (*CCL26*, *IL1R1* and *NTRK1*)<sup>56,61-63</sup>. Together, these results  
488 suggest that there is a common mechanism underlying the intrinsic changes that extend  
489 between the upper and lower airway epithelium in atopic asthmatic children, and while the  
490 differences may only affect a subset of genes (49 in total), they represent functionally  
491 important changes that are directly relevant to lower airway pathology.

492

493 Our study is not without limitations. Firstly, our study samples were collected from a  
494 community cohort, and although subgroups could be identified, better definition of these  
495 using strong accompanying criterion would strengthen the ability to compare results between  
496 these groups. Secondly, our sampling methodology obtained epithelial cells from the central  
497 airway, namely just above the carina. We were unable to sample deeper in the lung and thus  
498 our interpretations of a 'unified airway' are supportive of but limited to the central airway.  
499 Future studies may explore testing the hypothesis and comparing nasal and peripheral

500 bronchiolar epithelium. Thirdly, although our sampling methodology yields a >95% pure  
501 epithelial cell population, we acknowledge that our samples may not be entirely pure.  
502 Assessments of collected samples have identified a small population of macrophages (1-5%  
503 of sample) as well as a heterogeneous epithelial cell population consisting of both terminally  
504 differentiated epithelial cells as indicated by the presence of cilia and non-ciliated basal  
505 epithelial cells<sup>19</sup>. Our routine sample processing methodology positively selects out the  
506 macrophages<sup>18, 19</sup> and interrogation of resulting cell populations have confirmed that samples  
507 are not contaminated by other cell types, including; mesenchymal cells, macrophages,  
508 dendritic cells and endothelial cells<sup>18</sup>. Although these have been excluded we recognize that  
509 we may potentially have other cells types that would still be detected by RNA-seq. This is  
510 particularly so for immune cells including lymphocytes and monocytes which are known to  
511 have well characterized pathways/gene ontologies<sup>64, 65</sup>. In fact, modules identified as part of  
512 this study included pathways involved in T cell signaling and B cell signaling. Although  
513 beyond the scope of the current manuscript, future experiments could utilise single-cell  
514 sequencing to delineate the exact transcriptomic signature for each cell type in the airway  
515 epithelium<sup>66, 67</sup>. Finally, atopy was determined in this study using a RAST test. This was  
516 justified since it was directly measured at time of recruitment and additional information such  
517 as eczema and hayfever was only parent reported. Future studies would be strengthened if this  
518 information was confirmed as current manifestations and combined with RAST results to  
519 further define the atopy group.

520

521 Although data generated from this study indicates primary homology between the upper and  
522 lower airway, the importance of the unified airway hypothesis lies in its approach to therapy.  
523 The hypothesis assumes that commonalities between the nasal and tracheal mucosa are  
524 functionally complementary and thus can be treated in a unified fashion. Our observations

525 suggest that this the case, with biological conservation evident. Considering, since clinical  
526 evidence suggests that treating upper airway diseases such as rhinitis benefits the lower  
527 airway<sup>68-70</sup>, there is inference that certain functional complementarity between the nose and  
528 the lower airway may facilitate a unified approach to treatment.

529

### 530 *Conclusions and future directions*

531 Collectively, this study, the largest of its kind, has utilized transcriptomics to  
532 comprehensively and systematically compare upper and lower airway epithelial cells. Data  
533 generated identified 91% homology with the remainder being uniquely expressed to each  
534 region and associated with site-specific roles. There exists enormous interest as to whether  
535 nasal cells can act as an informative surrogate for the lower airway. Our findings suggest that  
536 this may be the case but dependent on whether both sites are affected to a similar extent and if  
537 both translate to similar functional outcome. With significant clinical interest also in  
538 biomarker discovery, and the use of nasal cells as an easily accessible surrogate for lower  
539 airway tissues, the conserved epithelial-signature identified in this study holds promise for  
540 development into a screening tool. While further work is required to determine the predictive  
541 value of these genes as biomarkers for chronic airway diseases, this unique data set provides a  
542 valuable resource for future meta-analyses or integrated -omic studies.

543

544 **ACKNOWLEDGEMENTS:** The authors thank the participants and their families in the  
545 Western Australian Epithelial Research Program (WAERP) for their contribution to this  
546 study. The members of WAERP include are: Anthony Kicic, Stephen M Stick, Darryl A  
547 Knight, Elizabeth Kicic-Starceвич, Luke W Garratt, Marc Padros-Goosen, Ee-Lyn Tan, Erika  
548 N Sutanto. Kevin Looi, Jessica Hillas, Thomas Iosifidis, Nicole C Shaw, Samuel T  
549 Montgomery, Kak-Ming Ling, Kelly M Martinovich, Francis J Lannigan, Ricardo Bergesio,

550 Bernard Lee, Shyan Vijaya-Sekaran, Paul Swan, Mairead Heaney, Ian Forsyth, Tobias  
551 Schoep, Alexander Larcombe, Monica Hunter, Kate McGee, Nyssa Millington. The  
552 Australian Respiratory Epithelium Consortium (AusREC) acknowledges the following  
553 members: Anthony Kicic, Stephen M Stick, Elizabeth Kicic-Starcevich, Luke W Garratt,  
554 Erika N Sutanto, Kevin Looi, Jessica Hillas, Thomas Iosifidis, Nicole C Shaw, Samuel T  
555 Montgomery, Kak-Ming Ling, Kelly M Martinovich, Matthew W-P Poh, Daniel R Laucirica,  
556 Craig Schofield, Samantha McLean, Katherine Landwehr, Emma de Jong, Nigel Farrow,  
557 Eugene Roscioli, David Parsons, Darryl A Knight, Christopher Grainge, Andrew T Reid, Su-  
558 Ling Loo, and Punnam C Veerati.

559

560

561 **REFERENCES**

- 562 1. Meena RS, Meena D, Aseri Y, Singh BK, Verma PC. Chronic Rhino-Sinusitis and  
563 Asthma: Concept of Unified Airway Disease (UAD) and its Impact in  
564 Otolaryngology. *Indian J Otolaryngol Head Neck Surg* 2013;65:338-342.  
565
- 566 2. Krouse JH. The Unified Airway—Conceptual Framework. *Otolaryngol Clin North*  
567 *Am* 2008;41:257-266.  
568
- 569 3. Mygind N. Rhinitis and asthma: similarities and differences., ed. P.U. Mygind N,  
570 Pipkorn U, Dahl R. 1990, Copenhagen: Munksgaard.  
571
- 572 4. Giavina-Bianchi P, Aun MV, Takejima P, Kalil J, Agondi RC. United airway disease:  
573 current perspectives. *J Asthma Allergy* 2016;9:93-100.  
574
- 575 5. Bachert C, Vignola AM, Gevaert P, Leynaert B, Van Cauwenberge P, Bousquet J.  
576 Allergic rhinitis, rhinosinusitis, and asthma: one airway disease. *Immunol Allergy*  
577 *Clin North Am* 2004;24:19-43.  
578
- 579 6. Fontanari P, Zattara-Hartmann MC, Burnet H, Jammes Y. Nasal eupnoeic inhalation  
580 of cold, dry air increases airway resistance in asthmatic patients. *Eur Respir J* 1997;  
581 10: 2250-2254.  
582
- 583 7. Jörres R, Nowak D, Magnussen H. The effect of ozone exposure on allergen  
584 responsiveness in subjects with asthma or rhinitis. *Am J Respir Crit Care Med*  
585 1996;153:56-64.  
586
- 587 8. Michel FB, Marty JP, Quet L, Lour P. Penetration of Inhaled Pollen into the  
588 Respiratory Tract 1, 2. *Am Rev Respir Dis* 1977;115:609-616.  
589
- 590
- 591 9. Platts-Mills TA. The role of allergens in allergic airway disease. *J Allergy Clin*  
592 *Immunol* 1998;101:S364-S366.

- 593
- 594 10. Chanez P, Vignola AM, Vic P, Guddo F, Bonsignore G, Godard P et al. Comparison  
595 between nasal and bronchial inflammation in asthmatic and control subjects. *Am J*  
596 *Respir Crit Care Med* 1999;159:588-595.
- 597
- 598 11. Gaga M, Lambrou P, Papageorgiou N, Koulouris NG Kosmas E, Fragakis S et al.  
599 Eosinophils are a feature of upper and lower airway pathology in non-atopic asthma,  
600 irrespective of the presence of rhinitis. *Clin Exp Allergy* 2000;30:663-669.
- 601
- 602 12. Braunstahl GJ, Overbeek SE, Fokkens WJ, Kleinjaqn A, McEuen AR, Walls AF et al.  
603 Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and  
604 basophil numbers in nasal and bronchial mucosa. *Am J Respir Crit Care Med*  
605 *2001;164:858-865.*
- 606
- 607 13. Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ.  
608 Nasal allergen provocation induces adhesion molecule expression and tissue  
609 eosinophilia in upper and lower airways. *J Allergy Clin Immunol* 2001;107:469-476.
- 610
- 611 14. Bourdin A, Gras D, Vachier I Chanez P. Upper airway. 1: Allergic rhinitis and  
612 asthma: united disease through epithelial cells. *Thorax* 2009;64:999-1004.
- 613
- 614 15. Togias A. Rhinitis and asthma: evidence for respiratory system integration. *J Allergy*  
615 *Clin Immunol* 2003;111:1171-1183.
- 616
- 617 16. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F et al. International  
618 Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. *Eur*  
619 *Respir J* 1995;8:483-491.
- 620
- 621 17. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). *Am*  
622 *Rev Respir Dis* 1978; 118:1-120.
- 623
- 624

- 625 18. Kicic A, Sutanto EN, Stevens PT, Knight DA, Stick SM. Intrinsic biochemical and  
626 functional differences in bronchial epithelial cells of children with asthma. *Am J*  
627 *Respir Crit Care Med* 2006;174:1110-1118.  
628
- 629 19. Lane C, Burgess S, Kicic A, Knight DA, Stick SM. The use of non-bronchoscopic  
630 brushings to study the paediatric airway. *Respir Res* 2005;6:53-63.  
631
- 632 20. Lane C, Knight DA, Burgess S, Franklin P, Horak F, Legg J *et al.* Epithelial inducible  
633 nitric oxide synthase activity is the major determinant of nitric oxide concentration in  
634 exhaled breath. *Thorax* 2004;59:757-760.  
635
- 636 21. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression  
637 and hybridization array data repository. *Nucleic Acids Res* 2002;30:207-210.  
638
- 639 22. Andrews S. FastQC A Quality Control tool for High Throughput Sequence Data.  
640 [cited 2017; Available from:  
641 <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>.  
642
- 643 23. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory  
644 requirements. *Nat Methods* 2015;12:357-360.  
645
- 646 24. Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R *et al.*  
647 Software for Computing and Annotating Genomic Ranges. *PLoS Compu Biol*  
648 2013;9:e1003118.  
649
- 650 25. Lassmann T, Hayashizaki Y, Daub CO. SAMStat: monitoring biases in next  
651 generation sequencing data. *Bioinformatics* 2011;27:130-131.  
652
- 653 26. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W *et al.* limma powers  
654 differential expression analyses for RNA-sequencing and microarray studies. *Nucleic*  
655 *Acids Res.* 2015;43:e47.  
656

- 657 27. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion  
658 for RNA-seq data with DESeq2. *Genome Biol* 2014;15:550.  
659  
660
- 661 28. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network  
662 analysis. *BMC Bioinformatics* 2008;9:559-559.  
663
- 664 29. Breuer K, Foroushani AK, Laird MR, Chen C, Sribnaia A, Lo R et al. InnateDB:  
665 systems biology of innate immunity and beyond—recent updates and continuing  
666 curation. *Nucleic Acids Res* 2013;41:D1228-D1233.  
667
- 668 30. Chen Y, Lun AT, Smyth GK. From reads to genes to pathways: differential expression  
669 analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood  
670 pipeline. *F1000Res* 2016;5:1438.  
671  
672
- 673 31. Li B, Tsoi LC, Swindell WR, Gudjonsson JE, Tejasvi T, Johnston A et al.  
674 Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides  
675 insights into disease mechanisms. *J. Invest. Dermatol* 2014;134:1828-1838.  
676
- 677 32. Jones AC, Bosco A. Using Network Analysis to Understand Severe Asthma  
678 Phenotypes. *Am J Respir Crit Care Med* 2017;195:1409-1411.  
679
- 680 33. Clarke LA, Sousa L, Barreto C, Amaral MD. Changes in transcriptome of native nasal  
681 epithelium expressing F508del-CFTR and intersecting data from comparable studies.  
682 *Respir Res* 2013;14:e38.  
683
- 684 34. Ogilvie V, Passmore M, Hyndman L, Jones L, Stevenson B, Wilson A et al.  
685 Differential global gene expression in cystic fibrosis nasal and bronchial epithelium.  
686 *Genomics* 2011;98:327-336.  
687

- 688 35. Court MH. Interindividual variability in hepatic drug glucuronidation: studies into the  
689 role of age, sex, enzyme inducers, and genetic polymorphism using the human liver  
690 bank as a model system. *Drug Metab Rev*, 2010;42:209-224.  
691
- 692 36. Ohno S, Nakajin S. Determination of mRNA expression of human UDP-  
693 glucuronosyltransferases and application for localization in various human tissues by  
694 real-time reverse transcriptase-polymerase chain reaction. *Drug Metab Dispos*,  
695 2009;37:32-40.  
696
- 697 37. Heydel JM, Holsztynska EJ, Legendre A, Thiebaud N, Artur Y, Le Bon AM. UDP-  
698 glucuronosyltransferases (UGTs) in neuro-olfactory tissues: expression, regulation,  
699 and function. *Drug Metab Rev*, 2010;42:74-97.  
700
- 701 38. Ouzzine M, Gulberti S, Ramalanjaona N, Magdalou Jm Fournel-Gigleux S. The UDP-  
702 glucuronosyltransferases of the blood-brain barrier: their role in drug metabolism and  
703 detoxication. *Front Cell Neurosci*, 2014;8:e349.  
704
- 705 39. Ross, AJ, Dailey LA, Brighton LE, Devlin RB. Transcriptional profiling of  
706 mucociliary differentiation in human airway epithelial cells. *Am J Respir Cell Mol*  
707 *Biol*, 2007;37:169-185.  
708
- 709 40. Jain R, Pan, J, Driscoll JA, Wisner JW, Huang T Gunsten SP et al. Temporal  
710 relationship between primary and motile ciliogenesis in airway epithelial cells. *Am J*  
711 *Respir Cell Mol Biol*, 2010;43:731-739.  
712
- 713 41. Wagner JA, Cozens AL, Schulman H, Gruenert DC, Stryer L, Gardner P. Activation  
714 of chloride channels in normal and cystic fibrosis airway epithelial cells by  
715 multifunctional calcium/calmodulin-dependent protein kinase. *Nature*, 1991;349:793-  
716 796.  
717
- 718 42. Huang F, Zhang H, Wu M, Yang H, Kudo M, Peters CJ et al. Calcium-activated  
719 chloride channel TMEM16A modulates mucin secretion and airway smooth muscle  
720 contraction. *Proc Natl Acad Sci USA*, 2012;109:16354-16359.

- 721  
722
- 723 43. Guajardo JR, Schleifer KW, Daines MO, Ruddy RM, Aronow BJ, Wills-Karp M et  
724 al.. Altered gene expression profiles in nasal respiratory epithelium reflect stable  
725 versus acute childhood asthma. *J Allergy Clin Immunol* 2005;115:243-251.  
726
- 727 44. Poole A, Urbanek C, Eng C, Schageman J, Jacobson S, O'Connor BP, et al.  
728 Dissecting Childhood Asthma with Nasal Transcriptomics Distinguishes  
729 Subphenotypes of Disease. *J Allergy Clin Immunol* 2014;133:670-678.  
730
- 731 45. Boudewijn IM, Faiz A, Steiling K, van der Wiel E, Telenga ED, Hoonhorst SJ, et al..  
732 Nasal gene expression differentiates COPD from controls and overlaps bronchial gene  
733 expression. *Respir Res* 2017;18:213.  
734
- 735 46. Zhang X, Sebastiani P, Liu G, Schembri F, Zhang X, Dumas YM, et al. Similarities  
736 and differences between smoking-related gene expression in nasal and bronchial  
737 epithelium. *Physiol Genomics* 2010;41:1-8.  
738
- 739 47. Sridhar S, Schembri F, Zeskind J, Shah V, Gustafson AM, Steiling K, et al. Smoking-  
740 induced gene expression changes in the bronchial airway are reflected in nasal and  
741 buccal epithelium. *BMC Genomics* 2008;9:259.  
742
- 743 48. Dickinson D. Salivary (SD-type) cystatins: over one billion years in the making—But  
744 to what purpose? *Crit Rev Oral Biol Med* 2002;13:485-508.  
745
- 746 49. Singhanian A, Wallington JC, Smith CG, Horowitz D, Staples KJ, Howarth PH, et al..  
747 Multitissue Transcriptomics Delineates the Diversity of Airway T Cell Functions in  
748 Asthma. *Am J Respir Cell Mol Biol* 2018;58:261-270.  
749
- 750 50. Imoto Y, Tokunaga T, Matsumoto Y, Hamada Y, Ono M, Yamada T, et al. I. Cystatin  
751 SN Upregulation in Patients with Seasonal Allergic Rhinitis. *PLoS One*  
752 2013;8:e67057.  
753

- 754 51. Fábíán TK, Hermann P, Beck A, Fejérdy P, Fábíán G. Salivary Defense Proteins:  
755 Their Network and Role in Innate and Acquired Oral Immunity. *Int J Mol Sci*  
756 2012;13:4295-4320.  
757
- 758 52. Lindahl M, Ståhlbom B, Tagesson C. Newly identified proteins in human nasal and  
759 bronchoalveolar lavage fluids: potential biomedical and clinical applications.  
760 *Electrophoresis* 1999;20:3670-3676.  
761
- 762 53. Alevy YG, Patel AC, Romero AG, Patel DA, Tucker J, Roswit WT, et al. IL-13–  
763 induced airway mucus production is attenuated by MAPK13 inhibition. *Journal Clin*  
764 *Invest* 2012;122:4555-4568.  
765
- 766 54. Brett TJ. CLCA1 and TMEM16A: The link towards a potential cure for airway  
767 diseases. *Expert Rev Respir Med* 2015;9:503-506.  
768
- 769 55. Winpenny JP, Marsey LL, Sexton DW. The CLCA gene family: putative therapeutic  
770 target for respiratory diseases. *Inflammation & Allergy-Drug Targets (Formerly*  
771 *Current Drug Targets-Inflammation & Allergy)* 2009;8:146-160.  
772
- 773 56. Zissler UM, Esser-von Bieren J, Jakwerth CA, Chaker AM, Schmidt-Weber CB.  
774 Current and future biomarkers in allergic asthma. *Allergy* 2016;71:475-494.  
775
- 776 57. Yuyama N, Davies DE, Akaiwa M, Matsui K, Hamasaki Y, Suminami Y, et al.  
777 Analysis of novel disease-related genes in bronchial asthma. *Cytokine* 2002;19:287-  
778 96.  
779
- 780 58. Walker JT, McLeod K, Kim S, Conway SJ, Hamilton DW. Periostin as a  
781 Multifunctional Modulator of the Wound Healing Response. *Cell and tissue research*  
782 2016;365:453-465.  
783
- 784 59. Nunomura S, Nanri Y, Ogawa M, Arima K, Mitamura Y, Yoshihara T et al.  
785 Constitutive overexpression of periostin delays wound healing in mouse skin. *Wound*  
786 *Repair and Regeneration* 2018;26:6-15.

- 787
- 788 60. Bentley JK, Chen Q, Hong JY, Popova AP, Lei J, Moore BB et al. Periostin is  
789 required for maximal airways inflammation and hyperresponsiveness in mice. *J*  
790 *Allergy Clin Immunol.* 2014;134:1433-1442.
- 791
- 792 61. Bhakta NR, Solberg OD, Nguyen CP, Nguyen CN, Arron JR, Fahy JV, et al. A qPCR-  
793 based metric of Th2 airway inflammation in asthma. *Clin Translational Allergy*  
794 2013;3:24-24.
- 795
- 796 62. Traister RS, Uvalle CE, Hawkins GA, Meyers DA, Bleecker ER, Wenzel SE.  
797 Phenotypic and genotypic association of epithelial IL1RL1 to human T(H)2-like  
798 asthma. *J Allergy and Clin Immunol* 2015;135:92-99.e10.
- 799
- 800 63. Szczepankiewicz A, Rachel M, Sobkowiak P, Kycler Z, Wojsyk-Banaszak I,  
801 Schöneich N. Neurotrophin serum concentrations and polymorphisms of  
802 neurotrophins and their receptors in children with asthma. *Respir Med* 2013;107:30-  
803 36.
- 804
- 805 64. Reynolds LM, Ding J, Taylor JR, Lohman K, Soranzo N, de la Fuente A et al.  
806 Transcriptomic profiles of aging in purified human immune cells. *BMC Genomics*  
807 2015;16:e333.
- 808
- 809 65. Mirsafian H, Ripen AM, Leong WM, Manaharan T, Mohamad SB, Merican  
810 AF. Transcriptome landscape of human primary monocytes at different sequencing  
811 depth. *Genomics* 2017;109:463-470.
- 812
- 813 66. Baslan T, Hicks J. Unravelling biology and shifting paradigms in cancer with single-  
814 cell sequencing. *Nat Rev Cancer* 2017;17:557-569.
- 815
- 816 67. Kolodziejczyk AA, Kim JK, Svensson V, Marioni JC, Teichmann SA. The technology  
817 and biology of single-cell RNA sequencing. *Mol Cell* 2015;58:610-620.
- 818

- 819 68. Agondi RC, Machado ML, Kalil J, Giavina-Bianchi P. Intranasal corticosteroid  
820 administration reduces nonspecific bronchial hyperresponsiveness and improves  
821 asthma symptoms. *J Asthma* 2008;45:754-757.  
822
- 823 69. Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthma  
824 outcomes in allergic rhinitis: a meta-analysis. *Allergy* 2013;68:569-579.  
825
- 826 70. Crystal-Peters J, Neslusan C, Crown WH, Torress A. Treating allergic rhinitis in  
827 patients with comorbid asthma: the risk of asthma-related hospitalizations and  
828 emergency department visits. *J Allergy Clin Immunol* 2002;109:57-62.  
829  
830  
831

832 **FIGURE LEGENDS**

833 **Figure 1. Conserved transcriptional profiles between tracheal and nasal epithelium. (A)**  
834 Venn diagram comparing genes with evidence of expression in all tracheal, and all nasal  
835 epithelial samples, independent of asthma or atopy. **(B)** Scatter plot of the average gene  
836 counts per million (CPM) reads, for all expressed genes between tracheal and nasal epithelial  
837 samples (across all groups). Colours represent genes identified as more frequently expressed  
838 in tracheal or nasal epithelium (green and purple, respectively), or common to both sites  
839 (grey).

840

841 **Figure 2. Identification of a consensus gene expression network between tracheal and**  
842 **nasal epithelium. (A)** WGCNA was used to identify modules of co-expressed genes within  
843 the upper or lower airway. Cluster dendrograms for the tracheal and nasal networks  
844 containing 17 and 8 modules respectively, are shown alongside the correspondence matrix  
845 between the two networks. Here, numbers within the table represent the number of genes that  
846 overlap between the modules being compared, where a stronger colour indicates a more  
847 significant overlap based on a Fisher's exact test p-value. **(B)** The consensus network  
848 containing 16 modules that are shared across the tracheal and nasal networks. Each network  
849 module is represented by a different colour. **(C)** The relative expression of all genes within  
850 each consensus module represented as the median  $\log_2$  fold-change between tracheal and  
851 nasal epithelial cell samples, where box plots represent the results across all four study groups  
852 i.e. comparisons between tissues were performed independently for each phenotype based on  
853 atopy/wheeze.

854

855 **Figure 3. Lower airway disease-signature is reflected in the upper airway. (A)**  
856 Dendrogram representing the weighted correlation network analysis across tracheal epithelial  
857 samples, with each distinct module marked by a unique colour. **(B)** Each network module was  
858 tested for enrichment of differentially expressed genes (between atopic asthmatics and healthy  
859 controls within tracheal epithelium), where the horizontal dashed line represents the threshold  
860 for significance. Module E was highly enriched for differentially expressed genes. **(C)**  
861 Heatmaps visualising expression patterns for the 92 genes within module E across all nasal  
862 epithelial samples (left) and tracheal epithelial samples (right), where genes and samples were

863 ranked using unsupervised clustering. **(D)** Principal component analysis across all samples  
864 based on the 92 genes within module E.

865 **Figure 4. Similar expression of key disease-associated genes within tracheal and nasal**  
866 **epithelium.** Normalised gene counts for selected genes representing the most robust gene  
867 expression changes across tissues, or hub genes within the protein-protein interaction network  
868 for the wheeze with atopy network module. P-values were derived from DESeq2 analysis for  
869 differential gene expression (disease group relative to healthy controls) and adjusted for  
870 multiple comparisons using the Benjamini-Hochberg method. Data points represent individual  
871 samples with bars showing median values. \* $p \leq 0.05$ , \*\* $p \leq 0.001$ , \*\*\* $p \leq 0.0001$ ,  
872 \*\*\*\* $p \leq 0.00001$ .

873

874

**Table 1. Demographic information for study participants**

	<b>Healthy controls</b>	<b>Wheeze with atopy</b>	<b>Atopy only</b>	<b>Wheeze only</b>	<b>p-value</b>
<b>Number of participants</b>	<b>16</b>	<b>15</b>	<b>16</b>	<b>16</b>	
<u>Samples from participants:</u>					
Paired TEC and NEC	13	10	13	4	
TEC only	2	1	2	3	
NEC only	1	4	1	9	
Age: median (yr)	3.3	6.4	3.8	3.5	0.052
(range, yrs)	(2.8–6.8)	(4.0–18.3)	(2.8–5.5)	(2.8–7.6)	
Male (%)	50	60	50	56	0.81
<u>RAST results (% positive):</u>					
Grass pollen	0	80	38	0	<0.0001
Animal	0	60	38	0	<0.0001
Mould	0	40	25	0	0.0035
Egg white	0	33	44	0	0.0012
House dust mite	0	53	38	0	0.0002
Past wheeze (%)	19	93	31	100	<0.0001
Current wheeze (%)	19	80	19	75	0.0005
Hay fever (%)	6	87	44	31	<0.0001
Family history of hay fever (%)	75	87	75	75	0.83
Eczema (%)	19	60	75	37	0.0084
Family history of eczema (%)	37	53	50	75	0.19
Parental asthma (%)	37	*40	37	87	0.01
Parental smoking (%)	19	13	6	44	0.051
For comparison of age across groups, the p-value was derived from Kruskal-Wallis test with Dunn's multiple comparisons test for non-parametric data (data for each group checked using the D'Agostino & Pearson normality test). Age is reported as median (inter-quartile range). For comparisons of categorical variables, p-values were derived from a Chi-square test across the four groups. All percentages are rounded to the nearest whole number. *Data was missing for one participant. TEC, tracheal epithelial cells; NEC, nasal epithelial cells.					

**Table 2. Nasal epithelial cell network module preservation within tracheal epithelial cell network modules**

Nasal Network Module		Generalised biological function (Supplementary Table 1)	Module size	Preservation Z-score summary
1	Brown	Immune response, antigen presentation	1484	57.8
2	Green	Ribosome activity	947	56.6
3	Red	Innate immune response, interferon signalling	350	56.5
4	Blue	Cell cycle, centrosome activity	3738	49.1
5	Yellow	Adaptive immune response, B and T cell activity	1030	38.5
6	Turquoise	Metabolism, growth factor signalling	3845	15.6
7	Black	Cell cycle	185	15.2
8	Grey	No collective function (contains genes not associated with any module)	371	2.3
Total genes in network			11,950	

**Table 3. Tracheal epithelial cell network module preservation within nasal epithelial cell network modules**

Tracheal Network Module		Generalised biological function (Supplementary Table 2)	Module size	Preservation Z-score summary
1	Cyan	Regulation of transcription	379	67.0
2	Black	Cilium/cell cycle	789	61.3
3	Magenta	Cilium activity and hedgehog signalling	610	58.6
4	Red	Ribosome activity	859	46.3

5	Turquoise	Immune response	1770	45.4
6	Midnight blue	Immune response (adaptive)	136	39.1
7	Salmon	Cell cycle/movement	443	34.1
8	Light cyan	Apoptosis	94	30.7
9	Purple	Anti-viral immune response (interferons)	582	30.4
10	Tan	NOTCH signalling/metabolism	508	27.9
11	Brown	Mitochondrial activity	1238	27.5
12	Yellow	Transcription, gene expression	995	24.1
13	Green yellow	Gene expression, proteasome activity	520	21.1
14	Blue	Regulation of gene expression (chromatin activity)	1295	14.8
15	Pink	Lysosome, phagosome activity	621	14.4
16	Green	Cellular growth	918	13.9
17	Grey	No collective function (contains genes not associated with any module)	193	6.6
Total genes in network			11,950	

**Table 4. Summary of differentially expressed genes between atopic and or asthmatics and non-atopic healthy controls in tracheal and nasal epithelium**

Contrast: description	# of differentially expressed genes (adjusted p-value <0.05)		
	Tracheal	Nasal	Overlap
Wheeze with atopy vs healthy controls: Effect of wheeze and asthma	<b>340</b> (98 down, 242 up)	<b>103</b> (13 down, 90 up)	<b>49</b> (2 down, 47 up)

<b>Atopy only vs healthy controls: Effect of atopy only</b>	<b>95</b> (55 down, 40 up)	<b>38</b> (1 down, 37 up)	<b>18</b> (1 down, 17 up)
<b>Wheeze only vs healthy controls: Effect of wheeze only</b>	<b>8</b> (3 down, 5 up)	<b>41</b> (25 down, 16 up)	<b>4</b> (1 down, 3 up)
<b>Wheeze with atopy vs atopy only: Effect of wheeze in presence of atopy</b>	<b>34</b> (23 down, 11 up)	<b>3</b> (1 down, 2 up)	<b>2</b> (1 down, 1 up)







